FDA Sets Biosimilar Application Fees, But Is Silent On Volume Projections
This article was originally published in The Pink Sheet Daily
Executive Summary
A Federal Register notice outlines the new user fee amounts and suggests that President Obama’s budget projections anticipated as many as 10 marketing applications, but the mix of INDs and full applications is unknown.